EMA Says No New Approval Needed for Mounjaro in Sleep Apnea

Summary: The European Medicines Agency (EMA) has determined that Eli Lilly’s Mounjaro (tirzepatide), approved for weight management, does not require a separate indication for treating obstructive sleep apnea (OSA) in adults with obesity. Clinical data from two studies showed Mounjaro improves OSA symptoms by reducing weight. However, the EMA concluded these benefits are already covered…

Read More

Wearable EEG Reveals Sleep Challenges in Lennox-Gastaut Syndrome and Their Caregivers

Summary: Beacon Biosignals presented two studies at the American Epilepsy Society Annual Meeting, focusing on sleep disturbances in individuals with Lennox-Gastaut Syndrome (LGS) and their caregivers. Using the FDA-cleared Dreem 3S EEG headband, the studies identified significant sleep fragmentation and reduced REM sleep in LGS patients and caregivers. Caregivers showed higher wake after sleep onset…

Read More

Screen Time May Disrupt Sleep and Fuel Hyperactivity in Young Children

Summary: Excessive screen time among preschool-aged children is linked to reduced sleep quality, which contributes to behavioral challenges such as hyperactivity, attention difficulties, and emotional instability. A study involving 571 children found that screen use disrupts sleep patterns, likely due to delayed bedtimes, overstimulation, and blue-light exposure. The findings emphasize the interplay between screen time…

Read More

Spanish Physicists Defend Seasonal Time Change Against British Sleep Society’s Stance

Summary: Spanish physicists Jorge Mira Pérez and José María Martín Olalla defend the seasonal time change in the United Kingdom, countering the British Sleep Society’s call to abolish it. In a study published in the Journal of Sleep Research, the researchers highlight how the time change synchronizes human activity with morning light, provides extra evening…

Read More

Nyxoah’s Genio Neurostimulator for OSA Launches in England

Summary: Nyxoah SA has launched its Genio neurostimulator for the treatment of obstructive sleep apnea (OSA) in England. The battery-free hypoglossal neuromodulation system, which is inserted through an incision and controlled by a wearable, is now available under the NHS Specialised Services Devices Programme. The first successful implants were performed at University College London Hospitals.…

Read More